Coverage at a glance
| Indication | Coverage |
|---|---|
| Type 2 diabetes | Covered with prior authorization |
| Weight loss / chronic weight management | Not covered |
Plan type: Commercial non-Medicare. Each indication below lists the BMI and clinical thresholds, the prior-authorization documentation, and the published policy it comes from.
If the weight-loss exclusion above applies to you, you are paying for this yourself.
Coverage by indication
| Step therapy | Yes. A member needs at least a 3 month trial of metformin with an A1C at or above 7 percent (metformin-naive members qualify for concurrent use at an A1C at or above 8.5 percent). Because Mounjaro is a non-preferred GLP-1 agent, the current master policy also requires failure of the preferred GLP-1 drugs first, at least 3 consecutive months each of liraglutide (Victoza) then Trulicity, unless each is contraindicated or caused clinically significant adverse effects. The older marketplace version of the policy required failure of Victoza, Trulicity and Ozempic before Mounjaro. |
What the prior authorization needs:
- Diagnosis of type 2 diabetes
- Age 18 or older (the current master policy allows age 10 or older for Mounjaro)
- At least a 3 month trial of metformin with an A1C at or above 7 percent, unless contraindicated or not tolerated, or a metformin-naive member with an A1C at or above 8.5 percent starting Mounjaro alongside metformin
- Mounjaro is non-preferred, so a documented failure of the preferred GLP-1 drugs first: at least 3 consecutive months each of liraglutide (Victoza) then Trulicity, unless contraindicated or not tolerated
- Not prescribed at the same time as another GLP-1 receptor agonist or a DPP-4 inhibitor
- Requested dose does not exceed the FDA-approved maximum
- Prior authorization approval runs 12 months
Policy CP.PMN.183. Source: Centene Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, Reference Number CP.PMN.183, Effective Date 09.19.18, Last Review Date 02.26, section I.A Type 2 Diabetes Mellitus. Two official Centene clinical policy PDFs read in full: the current corporate master CP.PMN.183 (Last Review Date 02.26) published at ambetterhealth.com, and the health insurance marketplace version HIM.PA.53 (Line of Business HIM) published at ambetterhealth.com. Both list Mounjaro (tirzepatide) for type 2 diabetes as a non-preferred GLP-1 requiring a metformin trial and failure of preferred GLP-1 agents before approval. Cross-checked against the 2026 Ambetter formularies for Georgia (document code AMB25-GA-C-00023) and Florida (AMB25-FL-C-00023), both effective January 1 2026 and searched in full: Mounjaro is not listed, while the preferred diabetes GLP-1 drugs Ozempic, Rybelsus and Trulicity appear at Tier 2 with prior authorization and quantity limits.. Verified August 27, 2026.
Mounjaro carries no FDA weight-loss indication, so it is never authorized for weight management under the diabetes GLP-1 policy. The tirzepatide approved for weight loss is Zepbound, and Centene's marketplace policy for it states that use of Zepbound for the treatment of weight management is a benefit exclusion and will not be authorized. California is the exception, where Ambetter is sold as Ambetter from Health Net and most plans cover weight-loss drugs after prior authorization.
Policy CP.PMN.298. Source: Centene Clinical Policy: Tirzepatide (Zepbound), Reference Number CP.PMN.298, section I.B and II.B, read alongside the Mounjaro prescribing information (Lilly, January 2026) confirming a type 2 diabetes indication only. Official Centene clinical policy PDF for tirzepatide (Zepbound), published at ambetterhealth.com, which states the weight-management benefit exclusion. Mounjaro's own FDA indication (type 2 diabetes only) is confirmed by the Mounjaro prescribing information cited within CP.PMN.183.. Verified August 27, 2026.
Recent change: Centene's CP.PMN.183 revision log records that in December 2024 the step therapy for non-preferred GLP-1 agents was modified from requiring failure of one preferred agent to requiring failure of the preferred agents in a stepwise order, first liraglutide (Victoza) then Trulicity. The February 2026 review added Mounjaro as an agent with proven cardiovascular or renal benefit per the 2026 ADA guidelines and added a pediatric age expansion to 10 years and older for Mounjaro. The weight-loss exclusion for tirzepatide is unchanged.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it. Plans that approve reassess at renewal, so know your long-term maintenance dose before you start.
- Browse the prior-authorization letter library for a template that matches your plan and indication.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- If the prior-authorization request is denied, the appeal letter library has templates by denial reason, covering peer-to-peer review, Level 1 and Level 2 internal appeal, and external review.
- If your plan does not cover the indication you need, compare cash prices in the cost guide or check whether a clinical trial near you fits. Neither one goes through your insurer. Clinical trials cost nothing and many pay you for your time. Some participants get a placebo, decided at random.
What it costs without insurance
The programs below bill you directly.
Frequently asked questions
Does Ambetter cover Mounjaro?
It varies by state. Where Mounjaro is on the plan's drug list, Ambetter covers it for type 2 diabetes with prior authorization and step therapy, but some state formularies leave it off entirely. The Centene GLP-1 policy that governs Ambetter marketplace plans (CP.PMN.183) treats Mounjaro (tirzepatide) as a non-preferred agent, so approval needs a diagnosis of type 2 diabetes, an A1C at or above 7 percent after at least 3 months on metformin, and a documented failure of the plan's preferred GLP-1 drugs first. Ambetter will not cover Mounjaro for weight loss. Mounjaro is FDA-approved for type 2 diabetes only, and the tirzepatide approved for weight loss is Zepbound, which Ambetter marketplace plans exclude outside California. This reflects the published policy verified August 2026.
What does Ambetter require to approve Mounjaro?
For type 2 diabetes: Yes. A member needs at least a 3 month trial of metformin with an A1C at or above 7 percent (metformin-naive members qualify for concurrent use at an A1C at or above 8.5 percent). Because Mounjaro is a non-preferred GLP-1 agent, the current master policy also requires failure of the preferred GLP-1 drugs first, at least 3 consecutive months each of liraglutide (Victoza) then Trulicity, unless each is contraindicated or caused clinically significant adverse effects. The older marketplace version of the policy required failure of Victoza, Trulicity and Ozempic before Mounjaro.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources; those rows are marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit. Those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
